QIMR Bergdorfer Medical Research Institute
QIMR Berghofer Licenses Esophageal Cancer Blood Biomarkers to Proteomics International
Under the agreement, Proteomics International has the right to use the markers to develop and commercialize a blood-based early detection test for esophageal cancer.
GenomiQa, Icon Group to Validate Genomic Analysis Platform CapeDx in Australia
A pilot study enrolling up to 15 patients will validate CapeDx's utility to match patients to approved drugs and clinical trials based on whole-genome and tumor sequencing.